Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Once-Monthly Risedronate for Osteoporosis Enters PIII: Takeda, Ajinomoto
April 5, 2010
- Bayer Transfers Imaging Agent to I'rom
April 5, 2010
- Dabigatran Reduces Strokes More Than Warfarin in AF
April 5, 2010
- 13 Products, Including Takeda's Rozerem, Recommended for Approval
April 5, 2010
- Korosho to Consider Introduction of “Special Nurses”
April 5, 2010
- Korosho to Approve Orphan Drugs Earlier
April 5, 2010
- Reclassification to Be Considered for 7 Class 1 OTC Drugs
April 5, 2010
- Industry Should Be Prepared for Discussions to Perpetuate New Pricing System: Mr Nagano
April 5, 2010
- Combination Eye Drops Improve Compliance: Prof. Yamamoto
April 5, 2010
- Application for Eritoran to Be Delayed Until March 2011: Eisai
April 5, 2010
- IFN Beta + Ribavirin Added to First-Line Therapy for Hepatitis C
April 5, 2010
- Alogliptin Applied for Combination with SU, BU as Additional Indications
April 5, 2010
- Cooperation of Pharmacists and Nurses Is Necessary for XELOX Therapy
April 5, 2010
- Dr Kondo Reappointed PMDA Chief Executive
April 5, 2010
- Erbitux Approved for Use in First-Line Therapy
April 5, 2010
- NovoSeven Approved for Bleeding in Congenial FVII Deficiency Patients
April 5, 2010
- Shionogi to Break from Long-Listed Drugs
April 5, 2010
- Korosho to Lift 14-Day Limit on Prescriptions of Thalidomide
April 5, 2010
- Hisamitsu Launches Fentanyl Transdermal System in the US
April 5, 2010
- Korosho Explains New Premium to Semi-Public Hospital Groups
April 5, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…